GLIOMATCH: Advancing Glioblastoma Research at KU Leuven

In this episode, we visit KU Leuven in Belgium to explore GLIOMATCH, a groundbreaking European research initiative working to improve outcomes for adults and children with glioblastoma through collaboration across neurosurgery, oncology, immunology, and spatial omics. We speak with the experts leading this innovative work. Frederik De Smet, Professor and GLIOMATCH Project Coordinator at KU Leuven, outlines the vision for the project and how it brings together multiple disciplines to tackle one of the most challenging forms of cancer. Steven De Vleeschouwer, MD, PhD, Neurosurgeon and expert in immunotherapy trials, shares how surgical intervention plays a key role not only in treatment but also in advancing research. Paul M. Clement, MD, Medical Oncologist specializing in adult neuro-oncology, discusses the complexities of post-surgical care and how GLIOMATCH is helping improve decision-making. Sandra Jacobs, MD, Pediatric Neuro-Oncologist, highlights the unique challenges in treating children and the need for tailored research approaches. Thierry Voet, PhD, Chair of the Leuven Institute for Single-Cell Omics, explains how cutting-edge spatial omics is transforming our understanding of glioblastoma biology. Abhishek D. Garg, PhD, Tumor Immunology Specialist, shares how data science and deep immune profiling are driving new insights into overcoming immunotherapy resistance. GLIOMATCH is a testament to the power of collaboration in pushing the boundaries of glioblastoma research and offering hope for patients and families worldwide. This work is funded by the European Union. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them. This work is also supported by Innovate UK [grant number 10113516] and the Swiss State Secretariat for Education, Research and Innovation (SERI) under the contract number 23.00607. Learn more at www.gliomatch.eu This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.